

Vienna Cancer Stem Cell Meeting 2024

20 Years Anniversary

4th - 5th July 2024

Van Swieten Saal, Medical University of Vienna Van-Swieten-Gasse 1a, 1090 Vienna

www.meduniwien.ac.at

DEPARTMENT OF MEDICINE I





We celebrate 20 years since the first Vienna Stem Cell Meeting and invite all interested colleagues to a Jubilee Meeting and Celebration.

We have prepared a scientific agenda with national and international experts who will present the latest developments in the field of neoplastic stem cells.

Wednesday, 3rd July 2024

7.00 pm
Welcome Reception

Thursday, 4th July 2024

8.30 – 9.15 am Welcome Coffee

9.15 – 9.30 am

Welcome Notes and Introduction

Peter Valent

9.30 - 11.00 am

Session I

Leukemic Stem Cells in Ph+ CML and ALL

Chairs: Jiří Mayer, Peter Valent

Markers and Targets in LSC in ALL and CML BP Gillian Horne

Measuring and Monitoring LSC in Ph⁺ CML Martin Culen, Jiří Mayer

Subclone-Specific Comprehensive Diagnostics and Prognostication in Ph+ CML and Ph+ ALL
Thomas Lion

11.00 – 11.30 am Coffee Break

11.30 am - 1.00 pm

Session II

Neoplastic Stem Cells in MPN and Leukemias

Chairs: Hans-Peter Horny, Kimmo Porkka

Hematologic Dissemination of LSC and CSC in Various Cancer Models: Mechanisms and Targeting Daniel Wicklein

LSC Phenotyping in CMML, MPN and sAML

Daniel Ivanov

Identification and Characterization of LSC in CLL

Rainer Hubmann

1.00 - 2.30 pm Lunch Break

2.30 - 4.00 pm **Session III**

Immunotherapy and Cell Therapy to Eliminate LSC

Chairs: Klaus Geissler, Philipp Staber

Stem Cell Transplantation in Advanced MastocytosisKaroline V. Gleixner

Stem Cell Transplantation in MDS and AML 2024Hildegard Greinix

Value of Antibody-Based Drug-Therapies and HSCT in the Treatment of Myeloid Neoplasms Dietger Niederwieser

4.00 – 4.30 pm Coffee Break 4.30 - 6.00 pm

Session IV

Novel Drugs and Concepts in Applied Hematology

Chairs: Hildegard Greinix, Dietger Niederwieser

Prognostication and Therapy of HR MDS: Status 2024

Michael Pfeilstöcker

Novel Drugs and Treatment Concepts in Ph⁻ MPN
Maria-Theresa Krauth

Novel Drugs and Treatment Concepts to Maintain

Long-Term Remission in HR MDS and AML
Wolfgang R. Sperr

6.00 pm

Summary of Day 1

Peter Valent

7.00 pm
Faculty Dinner

Friday, 5th July 2024

8.30 – 9.00 am Welcome Coffee

9.00 - 11.00 am

Session V

The Leukemic BM Microenvironment: LSC Niche Chairs: Udo Schumacher, Gregor Hoermann

Histopathologic Assessment of BM Fibrosis, Sclerosis and Angiogenesis in Myeloid Neoplasms Karl Sotlar

Diagnostic Value of Immunohistologic Application of 'Stem Cell Markers' in Myeloid Malignancies Hans-Peter Horny

Niche-Mediated Resistance of LSC in Ph⁺ CML
Barbara Peter

Regulation of Cancer Stemness in the CSC NicheJyotsna Batra

11.00 – 11.30 am Coffee Break 11.30 am - 1.00 pm

Session VI

Diagnosis and Therapy in Overlap Neoplasms

Chairs: Karl Sotlar, Michael Pfeilstöcker

Diagnosis, Prognostication, and Therapy in CMML in the Era of Personalized Precision Medicine

Klaus Geissler

New Treatment Strategies for Patients with SM-AHN Andreas Reiter

Treatment Algorithms in MDS and CMML:

Status 2024 Lisa Pleyer

1.00 - 2.00 pm **Lunch Break**

 $2.00 - 4.00 \, \text{pm}$

Session VII

Identification and Validation of New Markers and New Therapeutic Targets in Hematology

Chairs: Lisa Pleyer, Andreas Reiter

KIT Mutations and H α T in SM: Implications for Diagnosis, Prognostication and Therapy Michel Arock

Targeting LSC in CMML and Mast Cell Leukemia Peter Valent

Targeting the Homing-Molecules of CSC and LSC Udo Schumacher

4.00 - 4.30 pm Coffee Break

 $4.30 - 6.00 \, \text{pm}$ Session VIII

New Precision Medicine Concepts in LSC Research Chairs: Thomas Lion, Michel Arock

Diagnostic Precision Medicine Tools in Hematology Gregor Hoermann

Generating Reliable Evidence for Precision **Cancer Care by Federated Learning** Kimmo Porkka

Personalized Precision Medicine Therapy in Leukemia and Lymphoma: Status 2024 Philipp Staber

Summary and End of Meeting

Peter Valent

Faculty

Michel Arock, Sorbonne University Paris, France

Jyotsna Batra, Queensland University of Technology Brisbane, Australia

Martin Culen, Masaryk University Brno, Czech Republic

Klaus Geissler, Sigmund Freud University, Vienna, Austria

Karoline V. Gleixner, Medical University of Vienna, Austria

Hildegard Greinix, Medical University of Graz, Austria

Gregor Hoermann, MLL Munich Leukemia Laboratory, Munich, Germany

Gillian Horne, University of Glasgow, UK

Hans-Peter Horny, Ludwig Maximilians University of Munich, Germany

Rainer Hubmann, Medical University of Vienna,

Daniel Ivanov, Medical University of Vienna, Austria

Maria-Theresa Krauth, Medical University of Vienna, Austria

Thomas Lion, Children's Cancer Research Institute, Vienna. Austria

Jiří Mayer, Masaryk University Brno, Czech Republic

Dietger Niederwieser, University of Leipzig, Germany

Barbara Peter, Ludwig Boltzmann Institute for Hematology and Oncology, Vienna, Austria

Michael Pfeilstöcker, Hanusch Hospital Vienna, Austria

Lisa Pleyer, Paracelsus Medical University Salzburg, Austria

Kimmo Porkka, University of Helsinki, Finland

Andreas Reiter, University Clinic Mannheim, Germany

Udo Schumacher, University Medical Center Hamburg-Eppendorf, Germany

Karl Sotlar, Paracelsus Medical University Salzburg, Austria

Wolfgang R. Sperr, Medical University of Vienna, Austria

Philipp Staber, Medical University of Vienna, Austria

Peter Valent, Medical University of Vienna, Austria

Daniel Wicklein, University of Marburg, Germany

With the kind support of

abbvie











Van Swieten Saal, Medical University of Vienna Van-Swieten-Gasse 1a 1090 Vienna

In collaboration with:





DFP Die Teilnahme an dieser Veranstaltung wird mit je APPROBIERT 16 DFP-Punkt der Ärztekammer für Wien akkreditiert.

Please be aware that photographs and/or video footage will be taken at the event. These may be used for the purpose of documenting or reporting the event and published in print and online media, on various social media platforms and on MedUni Vienna's website.